ACADIA Pharmaceuticals (ACAD) Projected to Post Quarterly Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) is anticipated to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $277.65 million for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.

ACADIA Pharmaceuticals Trading Down 1.7 %

Shares of ACAD traded down $0.34 during trading hours on Friday, reaching $19.95. 1,995,038 shares of the stock traded hands, compared to its average volume of 2,911,013. The company has a market cap of $3.32 billion, a P/E ratio of 25.58 and a beta of 0.37. The company's 50-day moving average price is $18.20 and its two-hundred day moving average price is $16.73. ACADIA Pharmaceuticals has a 52-week low of $14.15 and a 52-week high of $26.56.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ACAD. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a "hold" rating and a $22.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, StockNews.com downgraded shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $24.00.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.